{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Moderate to severe signs and symptoms such as edema, hypotension, and pulmonary', 'infiltrates (eg, blood and mucus in the lung).', 'Such reactions should be managed as clinically indicated and according to standard clinical', 'practice.', '29 October 2019', '21']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '3.0 OBJECTIVES AND ENDPOINTS', 'Objectives', 'Endpoints', 'Primary', 'To evaluate the efficacy of ANB019 in', 'Proportion of subjects achieving clinical', 'subjects with active GPP as measured by', 'response at Week 4 and Week 16. Clinical', 'the Clinical Global Impression (CGI)', 'response is defined as \"Very much', 'scale according to the modified Japanese', 'improved,\\' \"Much improved,\" and', 'Dermatology Association (JDA) severity', '\"Minimally improved\" on CGI scale', 'index total score', 'according to modified JDA severity index', 'total score', 'To assess the safety and tolerability of', 'Assessment of AEs', 'ANB019 in subjects with GPP', 'Potentially significant and clinically', 'important AEs, AESIs, SAEs, and AEs', 'leading to withdrawal', 'Physical examinations', 'Vital signs', '12-lead ECG', 'Clinical safety laboratory tests', '(hematology, biochemistry, and', 'urinalysis)', 'Secondary', 'To evaluate the effect of ANB019 on the', 'Change in modified JDA severity index', 'total and individual skin lesion symptoms', 'total skin lesions score (sum of erythema,', 'as measured by the modified JDA severity', 'erythema with pustules, edema) at all', 'index score', 'study visits', 'Change in affected BSA of erythema with', 'pustules, erythema, and edema as', 'measured by modified JDA severity index', 'at all study visits', 'To evaluate the effect of ANB019 on total', 'Change in total and individual scores in', 'and individual components of systemic', 'systemic manifestations and laboratory', 'manifestations and laboratory findings as', 'findings as measured by modified JDA', 'measured by modified JDA severity index', 'severity index at all study visits', 'score', 'To evaluate the effect of ANB019 on GPP', 'Proportion of subjects achieving a', 'using the GPPPGA', 'GPPPGA score of 0 or 1 at all study visits', 'Change from Baseline in GPPPGA scores', 'at all study visits', '29 October 2019', '22']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'To determine any treatment effect of', 'Change in PASI score to evaluate a', 'ANB019 in PP (if present) as measured', \"subject's overall PP disease state if\", 'Psoriasis Area Severity Index (PASI)', 'present at all study visits', 'To assess the effect of ANB019 on the', 'Change in Dermatology Life Quality', \"subject's quality of life\", 'Index (DLQI) total score at all study visits', 'To determine the PK of ANB019 in GPP', 'Serum concentration following ANB019', 'subjects', 'administration', 'Following first dose administration of', 'ANB019 these parameters will be determined:', 'Cmax, Tmax, AUC, and other parameters as', 'appropriate', 'To test for immunogenicity to ANB019', 'Presence of ADA', 'Exploratory', 'To explore the effects of ANB019 on skin', 'Skin biopsies biomarkers (including but', 'biopsy biomarkers', 'not limited to IL-17, IL-22, IL-8, dendritic', 'cells, epidermal thickness, and leukocytes', 'infiltration)', 'To assess the effect of ANB019 on', 'Change in serum cytokines as compared', 'inflammatory parameters such as serum', 'to baseline at Weeks 1, 4, 8, 12, 16, and', 'cytokines including but not limited to IL-8', '24', 'Provide photographic documentation of', 'Photographic documentation of lesions', 'lesions', 'To explore GPP-associated mutations and', 'Optional genetic testing (DNA and', 'additional pharmacogenomic analysis', 'mRNA)', '29 October 2019', '23']\n\n###\n\n", "completion": "END"}